

Progression Decision Point Outcome

Exagamglogene autotemcel for treating sickle cell disease [ID4016]

Dear stakeholders,

After receiving the external assessment report, NICE has assessed the evidence submissions and report to decide how this appraisal will progress. This appraisal will continue as a single technology appraisal and progress to technical engagement before preparation for the committee meeting on 8 February 2024.

Technical engagement will begin later this week (week commencing 27 November 2023).

As outlined in section 5.7.2 of [NICE health technology evaluations: the manual](#), technical engagement is only included where NICE considers it to be appropriate, helpful and proportionate.

The purpose of the technical engagement is to note and consider any evidence gaps and potential resolution ahead of the committee meeting and to consider any commercial or managed access proposals, as outlined in sections 5.6.18 to 5.6.26 of [NICE health technology evaluations: the manual](#). The external assessment report will be sent to stakeholders for comment alongside any supporting documentation, which may include:

- Company submission
- Stakeholder submissions
- Clarification questions and company responses
- External Assessment Group response to company factual accuracy check of external assessment report.

Stakeholders will have 28 calendar days to submit comments on the external assessment report.

Best wishes,

Celia

Celia Mayers (she/her)

Project Manager, Technology Appraisals & HST